CN108813596A - 一种杜仲籽油软胶囊的制备方法及其应用 - Google Patents
一种杜仲籽油软胶囊的制备方法及其应用 Download PDFInfo
- Publication number
- CN108813596A CN108813596A CN201810729990.0A CN201810729990A CN108813596A CN 108813596 A CN108813596 A CN 108813596A CN 201810729990 A CN201810729990 A CN 201810729990A CN 108813596 A CN108813596 A CN 108813596A
- Authority
- CN
- China
- Prior art keywords
- parts
- seed oil
- preparation
- eucommia ulmoides
- soft capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 55
- 239000007901 soft capsule Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 241000208689 Eucommia ulmoides Species 0.000 title claims abstract 13
- 239000000843 powder Substances 0.000 claims abstract description 56
- 239000001387 apium graveolens Substances 0.000 claims abstract description 38
- 241000208688 Eucommia Species 0.000 claims abstract description 31
- 239000003921 oil Substances 0.000 claims abstract description 19
- 235000019198 oils Nutrition 0.000 claims abstract description 18
- 235000003934 Abelmoschus esculentus Nutrition 0.000 claims abstract description 16
- 240000004507 Abelmoschus esculentus Species 0.000 claims abstract description 16
- 235000013871 bee wax Nutrition 0.000 claims abstract description 15
- 239000012166 beeswax Substances 0.000 claims abstract description 15
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 239000003292 glue Substances 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 239000000084 colloidal system Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 238000000498 ball milling Methods 0.000 claims description 5
- 230000036760 body temperature Effects 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 229920001971 elastomer Polymers 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000000463 material Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 abstract description 25
- 230000007547 defect Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 244000237330 gutta percha tree Species 0.000 description 41
- 230000000052 comparative effect Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 240000007087 Apium graveolens Species 0.000 description 6
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 6
- 235000010591 Appio Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 229960004488 linolenic acid Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 241000229722 Perilla <angiosperm> Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 206010038464 renal hypertension Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241001075517 Abelmoschus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 235000002770 Petroselinum crispum Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100468302 Rattus norvegicus Rest gene Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- -1 proportion science Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种杜仲籽油软胶囊的制备方法及其应用,该软胶囊由杜仲籽油35~45份、紫苏籽油10~18份、秋葵油6~10份、杜仲雄花粉浓缩提取液5~7份、芹菜籽粉3~5份、蜂蜡2~4份制作而成。本发明制得的杜仲籽油软胶囊不仅能双向对血压进行调控,同时配合紫苏籽油与秋葵油以最佳比例达到缓解杜仲籽油氧化的目的,延长杜仲籽油的保存期限,且该软胶囊通过科学配比,克服了杜仲籽油单一产品降血压的缺陷,使用方便。
Description
技术领域
本发明属于医药保健品技术领域,具体涉及一种杜仲籽油软胶囊的制备方法及其应用。
背景技术
高血压是常见病、多发病,据全国高血压抽样调查的结果,高血压的患病率随年龄的增加而增长,在45岁以后呈显著逐级升高,25-34岁组仅4%,至35-44岁组增高1倍,以后则每10岁患病率上升10%左右。高血压发病有很多因索,寒冷和海拔较高的地域方患病率高,年龄越大者、肥胖者、高盐摄入者、经常大量饮酒者血压水平高。大多数的高血压患者在血压升高早期仅有轻微的自觉症状,随着病情的发展,症状逐渐增多并明显,如手指麻木和僵硬、多走路时出现下肢疼痛等,严重时会引起脑卒中、心肌梗死、心力衰竭及慢性肾脏病等并发症,是严重危害人类健康、导致死亡的主要疾病之一。而今化药在高血压市场上占有主导地位,如β-阻滞剂、钙拮抗剂、血管紧张素酶抑制剂等,化药新药的推出也从出不穷,但服用化药降压必然带来一系列的副作用,如快速降压后的明显反弹、靶器官的损害、肾功能损害等。
杜仲(Eucommia ulmoides Oliv.)为杜仲科杜仲属多年生落叶乔木植物,是我国独有的名贵医用树种。杜仲翅果是杜仲树的果实,长3~4 cm,翅宽1.0~1.5cm,千粒重95g左右,果仁占果实质量的35%左右。杜仲翅果含油10%左右,脱壳后种仁含油率27% ~30%。研究表明,杜仲籽油含亚油酸11%、亚麻酸61%,是人体必需脂肪酸的天然来源,而亚油酸与亚麻酸具有明显的降压作用和预防脑血栓、心肌梗塞及抗肿瘤作用,因而杜仲籽油的开发利用前景广阔。据日本专家报道,杜仲对血压也具有“双向调节作用”。
相关研究指出,α-亚麻酸分子中存在三个共轭双键,有非常强的还原性,高温、空气中的氧气、紫外线以及一些重金属离子都可以将其氧化。用杜仲籽油直接制成杜仲籽油软胶囊,或仅在杜仲籽油中加入维生素E制成杜仲籽油软胶囊,有效期能延长到1年左右,超过有效期,会引起杜仲籽油酸败、α-亚麻酸含量下降等,严重影响杜仲籽油软胶囊的质量和用药安全,影响临床疗效。
苏子系唇形科一年生草本植物紫苏或白苏的种子,其榨出的油色泽淡黄,质澄清,气味清香,α-亚麻酸的含量高,油中n-3系与n-6系脂肪酸的比例约5:1,具有“三高”特性,高碘值,高干性,高不饱和甘油酯。秋葵油是用成熟的优质黄秋葵籽经物理工艺冷压榨提取的植物油,富含维他命、矿物质、蛋白质、维生素E、卵磷脂、钙、磷、铁、钾、镁等矿物质,经常食用可以促进血液循环,防止动脉硬化以及动脉硬化并发症、高血压、心脏病、心力衰竭、肾衰竭、脑出血、抗衰老,改善人脑记忆力,预防老年痴呆症、改善消化系统功能。
药用芹菜以旱芹为主,旱芹香气较浓,也称“香芹”。由于它们的根、茎、叶和籽都可以当药用,故又有“厨房里的药物”、“药芹”之称。现代药理研究表明芹菜具有降血压、降血脂的作用。由于芹菜的钙磷含量较高,所以它有一定镇静和保护血管的作用,又可增强骨骼,预防小儿软骨病。维吾尔医生认为芹菜籽有散气、消肿、利尿、开通阻滞、降血压等功效,在维吾尔药中主要用于治疗高血压、关节炎、类风湿关节炎、气滞性子宫炎、腹水、肾脏等疾病。
基于上述分析,一种双向调控血压,同时配合紫苏籽油与秋葵油以最佳比例达到缓解杜仲籽油氧化的目的,延长杜仲籽油的保存期限,且该软胶囊通过科学配比,克服了杜仲籽油单一产品降血压的缺陷,使用方便的杜仲籽油软胶囊是目前行业内急需的。
发明内容
鉴于上述不足,本发明的目的在于提供一种双向调控血压,同时配合紫苏籽油与秋葵油以最佳比例达到缓解杜仲籽油氧化的目的,延长杜仲籽油的保存期限,且该软胶囊通过科学配比,克服了杜仲籽油单一产品降血压的缺陷,使用方便的杜仲籽油软胶囊。
经过发明人进行大量摸索总结得出的,各组分用量在下述重量范围内制备出的杜仲籽油软胶囊具有生物活性物质高、富含丰富的果胶、蛋白质等,有效满足多营养、携带方便的特性。该杜仲籽油软胶囊通过如下方法制得:
一种杜仲籽油软胶囊,包括胶囊内容物与囊体,胶囊内容物由如下重量份配比的原料制成:杜仲籽油35~45份、紫苏籽油10~18份、秋葵油6~10份、杜仲雄花粉浓缩提取液5~7份、芹菜籽粉3~5份、蜂蜡2~4份;囊体由如下重量分配比的原料制成:明胶15~25份、甘油10~20份、纯水10~16份、硬酯酸3~5份。
进一步的,所述胶囊内容物由如下重量份配比的原料制成:杜仲籽油40份、紫苏籽油14份、秋葵油8份、杜仲雄花粉浓缩提取液6份、芹菜籽粉4份、蜂蜡3份;所述囊体由如下重量分配比的原料制成:明胶20份、甘油15份、纯水13份、硬酯酸4份。
一种杜仲籽油软胶囊的制备方法,包括如下步骤:
(1)胶囊内容物的制备:按重量份配比计,取杜仲籽油、紫苏籽油、秋葵油混合后加热,随后加入蜂蜡,待蜂蜡完全溶解后,停止加热,冷却至室温,再将杜仲雄花粉浓缩提取液与芹菜籽粉加入其中,边加边搅拌,待混合物完全均匀后,过胶体磨,得胶囊内容物备用;
(2)囊体的制备:按重量份配比计,将甘油和纯水注入溶胶罐内,加热搅拌,再加入明胶、硬酯酸,继续搅拌均匀后真空脱泡,制作得到囊体;
(3)软胶囊的制备:将胶囊内容物与囊体经压丸、定型、洗丸、干燥、拣丸和分装步骤,制备得到杜仲籽油软胶囊。
进一步的,所述杜仲雄花粉浓缩提取液由如下方法制备而成:杜仲雄花鲜花粉除杂、清洗、晾干后加入蒸馏水,并于低温下浸提4h,随后离心提取,收集上清液,重复提取三次,合并上清液,得杜仲雄花粉浓缩提取液。
进一步的,所述芹菜籽粉由如下方法制备而成:将芹菜籽过20目筛,除杂、清洗、晾干后,液氮冷冻3~5min,并置于球磨仪进行研磨破壁1~3min,得芹菜籽粉。
进一步的,所述混合温度50~70℃,混合时间20~40min,过胶体磨的次数是 1~3次。
进一步的,所述囊体搅拌加热温度60~70℃。
进一步的,所述压丸机转速2.0转/min,喷体温度41~43℃,胶皮厚度0.8mm,装量为1184~1376mg/粒。
本发明的有益效果在于:
1、本发明在低温下直接对芹菜籽进行研磨,避免了高温干燥引发的芹菜籽活性成分损失,得到了充分保留生物活性的芹菜籽粉,经本发明方法制得的芹菜籽粉无有机溶剂残留、无污染,芹菜籽中生物活性成分和营养成分含量都显著高于常规方法制得的芹菜籽粉,最大程度地保留了芹菜籽的活性成分。
2、本发明采用杜仲籽油、紫苏籽油、秋葵油、杜仲雄花粉浓缩提取液5~7份、芹菜籽粉为原料,配比科学,原料天然安全;且配合紫苏籽油与秋葵油以最佳比例达到缓解杜仲籽油氧化的目的,延长杜仲籽油的保存期限。
3、本发明中使用杜仲籽油、芹菜籽粉进行联合使用,得到一种双向对血压进行调控的软胶囊,且效果相比单独使用杜仲籽油及芹菜籽粉的降压作用更显著,经动物实验证实,该软胶囊对高血压患者具有明显的辅助治疗效果。
4、本发明无极端加工条件,对各种原料的营养活性成分保留较好,迎合消费者对健康食品的需求,且制作工艺简单,成本低,适合于工业化生产。
具体实施方式
实施例1
一种杜仲籽油软胶囊
(1)制备杜仲雄花粉浓缩提取液:杜仲雄花鲜花粉除杂、清洗、晾干后加入蒸馏水,并于低温下浸提4h,随后离心提取,收集上清液,重复提取三次,合并上清液,得杜仲雄花粉浓缩提取液;
(2)制备芹菜籽粉:将芹菜籽过20目筛,除杂、清洗、晾干后,液氮冷冻4min,并置于球磨仪进行研磨破壁2min,得芹菜籽粉;
(3)胶囊内容物的制备:取杜仲籽油40kg、紫苏籽油14kg、秋葵油8kg混合30min后,加热60℃,随后加入蜂蜡3kg,待蜂蜡完全溶解后,停止加热,冷却至室温,再将杜仲雄花粉浓缩提取液6kg、芹菜籽粉4kg加入其中,边加边搅拌,待混合物完全均匀后,过胶体磨2次,得胶囊内容物备用;
(4)囊体的制备:将甘油15kg、纯水13kg注入溶胶罐内,加热65℃搅拌,再加入明胶20kg、硬酯酸4kg,继续搅拌均匀后真空脱泡,制作得到囊体;
(5)软胶囊的制备:将胶囊内容物与囊体经压丸、定型、洗丸、干燥、拣丸和分装步骤,压丸机转速2.0转/min,喷体温度42℃,胶皮厚度0.8mm,装量为1192mg/粒,制备得到杜仲籽油软胶囊。
实施例2
一种杜仲籽油软胶囊
(1)制备杜仲雄花粉浓缩提取液:杜仲雄花鲜花粉除杂、清洗、晾干后加入蒸馏水,并于低温下浸提4h,随后离心提取,收集上清液,重复提取三次,合并上清液,得杜仲雄花粉浓缩提取液;
(2)制备芹菜籽粉:将芹菜籽过20目筛,除杂、清洗、晾干后,液氮冷冻3min,并置于球磨仪进行研磨破壁3min,得芹菜籽粉;
(3)胶囊内容物的制备:取杜仲籽油35kg、紫苏籽油10kg、秋葵油6kg混合20min后,加热50℃,随后加入蜂蜡2kg,待蜂蜡完全溶解后,停止加热,冷却至室温,再将杜仲雄花粉浓缩提取液5kg、芹菜籽粉3kg加入其中,边加边搅拌,待混合物完全均匀后,过胶体磨1次,得胶囊内容物备用;
(4)囊体的制备:将甘油10kg、纯水10kg注入溶胶罐内,加热60℃搅拌,再加入明胶15kg、硬酯酸3kg,继续搅拌均匀后真空脱泡,制作得到囊体;
(5)软胶囊的制备:将胶囊内容物与囊体经压丸、定型、洗丸、干燥、拣丸和分装步骤,压丸机转速2.0转/min,喷体温度41℃,胶皮厚度0.8mm,装量为1184mg/粒,制备得到杜仲籽油软胶囊。
实施例3
一种杜仲籽油软胶囊
(1)制备杜仲雄花粉浓缩提取液:杜仲雄花鲜花粉除杂、清洗、晾干后加入蒸馏水,并于低温下浸提4h,随后离心提取,收集上清液,重复提取三次,合并上清液,得杜仲雄花粉浓缩提取液;
(2)制备芹菜籽粉:将芹菜籽过20目筛,除杂、清洗、晾干后,液氮冷冻5min,并置于球磨仪进行研磨破壁3min,得芹菜籽粉;
(3)胶囊内容物的制备:取杜仲籽油45kg、紫苏籽油18kg、秋葵油10kg混合40min后,加热70℃,随后加入蜂蜡4kg,待蜂蜡完全溶解后,停止加热,冷却至室温,再将杜仲雄花粉浓缩提取液7kg、芹菜籽粉5kg加入其中,边加边搅拌,待混合物完全均匀后,过胶体磨3次,得胶囊内容物备用;
(4)囊体的制备:将甘油20kg、纯水16kg注入溶胶罐内,加热70℃搅拌,再加入明胶25kg、硬酯酸5kg,继续搅拌均匀后真空脱泡,制作得到囊体;
(5)软胶囊的制备:将胶囊内容物与囊体经压丸、定型、洗丸、干燥、拣丸和分装步骤,压丸机转速2.0转/min,喷体温度43℃,胶皮厚度0.8mm,装量为1376mg/粒,制备得到杜仲籽油软胶囊。
对比例1
一种杜仲籽油软胶囊
原料配比同实施例1,只是去除芹菜籽粉。
对比例2
一种杜仲籽油软胶囊
原料配比同实施例1,只是去除杜仲雄花粉浓缩提取液。
对比例3
原料配比同实施例1,只是去除芹菜籽粉和杜仲雄花粉浓缩提取液。
以下通过具体药效学试验证明本发明的有益效果。
试验例1
本发明药物对大鼠降血压作用的实验研究
(1)模型建立:按照经典Gold blatt方法造模,按两肾一夹法(2KIC)建立肾性高血压大鼠模型。SD大鼠在实验室适应性喂养1周,测定其基础血压。造模成功后,随机选择4组,使每组大鼠血压平均基本一致,每组10只:肾性高血压模型对照组(模型组),实施例1组、对比例1~3组,另外10只健康SD大鼠,不分离左肾动脉,不结扎,作为假手术对照组(假手术组)。
(2)方法:假手术组合模型组灌胃给予生理盐水,其余各组给予实施例与对比例中制备的软胶囊,每天灌胃1次,连续灌胃30d,观察各组大鼠的血压变化。
(3)指标检测:采用大鼠尾动脉测定压大鼠于40℃预热15-20min后用YS-1型大鼠尾压测定仪,分别在实验前、建模后4周及给实施例1组、对比例1组和对比例2组30d和90d的血压。在大鼠安静状态下连续测血压3次,求平均值作为测定结果。
(4)结果分析:用SPSS17.0统计软件进行数据处理,结果建立模型前6组动物的血压无显著性差异(P>0.05)。建立模型后,模型组和实施例1组、对比例1~3组的动物血压均有明显升高(P<0.01)。模型组用生理盐水灌胃后,动物的血压未见变化(P>0.05)。对比例1和对比例2组灌胃后,动物血压有所下降,但与模型组相比差异显著(P<0.05),与假手术组相比,动物血压较高,差异显著(P<0.05),与对比例3组相比,血压略低,差异有统计学意义(P<0.05)。实施例1组灌胃后,动物血压下降与模型组相比差异极显著(P<0.01),与假手术组相比差异不显著(P>0.05)。
表1不同组合提取物对大鼠血压的影响
。
注:与假手术组比较,ΔP<0.01,○P<0.05;与模型组比较,#P<0.05, *P<0.01。
试验结果,实施例1组、对比例1~3组灌胃后,动物的血压下降。肾性高血压大鼠模型在灌胃实施例1组、对比例1组和对比例2组14d后,血压开始下降,当灌胃90d 后,大鼠血压下降更为明显,尤其是实施例1组更接近于假手术组。试验表明,实施例1组合物有一定的降压作用,并且长期服用疗效更好。虽然对比例1、2组各自均显示对降血压作用具有一定效果,但将1、2两组联用后,在相同的生药剂量下,其降血压作用明显提高,说明本发明药物配伍产生了协同增效作用。
试验例2
为检验本发明的治疗效果,选取100例高血压病患者,随机分为对照组 和治疗组两组。诊断标准:收缩压等于或高于160mmHg(21.3kPa),舒张压等于或高于95mmHg(12.7kPa),两者有1项经核实,即可确诊。
治疗方法:
对照组采用复方降压片,口服,一次2片,一日3次;治疗组采用实施例1生产的软胶囊,一日3次,一次1粒;四周为一疗程。
根据《中药新药临床指导原则(第一辑)》中的疗效标准:显效:①舒张压下降10mmHg(1.3kPa)以上,并达到正常范围;②舒张压虽未将至正常,但以下降20mmHg(2.7kPa)或以上,须具备其中1 项;有效:①舒张压下降不及10mmHg(1.3kPa),但达到正常范围;②舒张压较治疗前下降10~19mmHg(1.3~2.5kPa),但未达到正常范围;③收缩压较治疗前下降30mmHg(4kPa);须具备其中1项;无效:未达以上标准。两组病例治疗两个疗程后疗效比较结果见表2。
表2两组病例治疗后疗效比较
。
统计结果显示,治疗组总有效率明显优于对照组(P<0.01)。
以上所述仅为本发明的最佳实施例,凡是依照本发明申请专利范围所做的均等变化及修饰,均属于本发明所覆盖的范围。
Claims (9)
1.一种杜仲籽油软胶囊,包括胶囊内容物与囊体,其特征在于,胶囊内容物由如下重量份配比的原料制成:杜仲籽油35~45份、紫苏籽油10~18份、秋葵油6~10份、杜仲雄花粉浓缩提取液5~7份、芹菜籽粉3~5份、蜂蜡2~4份;囊体由如下重量分配比的原料制成:明胶15~25份、甘油10~20份、纯水10~16份、硬酯酸3~5份。
2.根据权利要求1所述的软胶囊,其特征在于,所述胶囊内容物由如下重量份配比的原料制成:杜仲籽油40份、紫苏籽油14份、秋葵油8份、杜仲雄花粉浓缩提取液6份、芹菜籽粉4份、蜂蜡3份;所述囊体由如下重量分配比的原料制成:明胶20份、甘油15份、纯水13份、硬酯酸4份。
3.一种根据权利要求1或2所述软胶囊的制备方法,其特征在于,该方法包括如下步骤:
胶囊内容物的制备:按重量份配比计,取杜仲籽油、紫苏籽油、秋葵油混合后加热,随后加入蜂蜡,待蜂蜡完全溶解后,停止加热,冷却至室温,再将杜仲雄花粉浓缩提取液与芹菜籽粉加入其中,边加边搅拌,待混合物完全均匀后,过胶体磨,得胶囊内容物备用;
囊体的制备:按重量份配比计,将甘油和纯水注入溶胶罐内,加热搅拌,再加入明胶、硬酯酸,继续搅拌均匀后真空脱泡,制作得到囊体;
软胶囊的制备:将胶囊内容物与囊体经压丸、定型、洗丸、干燥、拣丸和分装步骤,制备得到杜仲籽油软胶囊。
4.根据权利要求3所述的制备方法,其特征在于,所述杜仲雄花粉浓缩提取液由如下方法制备而成:杜仲雄花鲜花粉除杂、清洗、晾干后加入蒸馏水,并于低温下浸提4h,随后离心提取,收集上清液,重复提取三次,合并上清液,得杜仲雄花粉浓缩提取液。
5.根据权利要求3所述的制备方法,其特征在于,所述芹菜籽粉由如下方法制备而成:将芹菜籽过20目筛,除杂、清洗、晾干后,液氮冷冻3~5min,并置于球磨仪进行研磨破壁1~3min,得芹菜籽粉。
6.根据权利要求3所述的制备方法,其特征在于,所述混合温度50~70℃,混合时间20~40min,过胶体磨的次数是 1~3次。
7.根据权利要求3所述的制备方法,其特征在于,所述囊体搅拌加热温度60~70℃。
8.根据权利要求3所述的制备方法,其特征在于,所述压丸机转速2.0转/min,喷体温度41~43℃,胶皮厚度0.8mm,装量为1184~1376mg/粒。
9.一种如权利要求3~8所述任意方法制得的杜仲籽油软胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810729990.0A CN108813596A (zh) | 2018-07-05 | 2018-07-05 | 一种杜仲籽油软胶囊的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810729990.0A CN108813596A (zh) | 2018-07-05 | 2018-07-05 | 一种杜仲籽油软胶囊的制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108813596A true CN108813596A (zh) | 2018-11-16 |
Family
ID=64135457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810729990.0A Pending CN108813596A (zh) | 2018-07-05 | 2018-07-05 | 一种杜仲籽油软胶囊的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108813596A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113209153A (zh) * | 2021-04-30 | 2021-08-06 | 江西普正制药股份有限公司 | 一种杜仲组合物、制备方法及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105476011A (zh) * | 2015-12-27 | 2016-04-13 | 刘家容 | 一种番茄红素软胶囊的制备方法 |
CN106362142A (zh) * | 2016-10-28 | 2017-02-01 | 武汉庄守和生物科技有限公司 | 一种可以降低血压的配方组合 |
CN106912952A (zh) * | 2017-02-24 | 2017-07-04 | 河南大学 | 一种具有降血脂功能的药物组合物及其胶囊制剂的制备方法 |
-
2018
- 2018-07-05 CN CN201810729990.0A patent/CN108813596A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105476011A (zh) * | 2015-12-27 | 2016-04-13 | 刘家容 | 一种番茄红素软胶囊的制备方法 |
CN106362142A (zh) * | 2016-10-28 | 2017-02-01 | 武汉庄守和生物科技有限公司 | 一种可以降低血压的配方组合 |
CN106912952A (zh) * | 2017-02-24 | 2017-07-04 | 河南大学 | 一种具有降血脂功能的药物组合物及其胶囊制剂的制备方法 |
Non-Patent Citations (5)
Title |
---|
娄丽杰等: "杜仲雄花茶对高钠饮食大鼠血压的影响 ", 《河南大学学报(医学版)》 * |
应森林等: "芹菜的药理研究和应用 ", 《天津中医学院学报》 * |
李勇等: "芹菜的最新研究进展 ", 《中国野生植物资源》 * |
杨炳坤等: "芹菜籽治疗高血压病25例 ", 《广西中医药》 * |
秦文 等: "《食品加工原理》", 30 June 2011, 中国质检出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113209153A (zh) * | 2021-04-30 | 2021-08-06 | 江西普正制药股份有限公司 | 一种杜仲组合物、制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106722963A (zh) | 一种素食餐 | |
CN108651806A (zh) | 一种全营养膳食纤维固体饮料及其制备方法 | |
CN1742927A (zh) | 枸杞桑椹片及其制备工艺 | |
CN1939475A (zh) | 枸杞葛根胶囊及其制备工艺 | |
CN101467582B (zh) | 九制益寿茶 | |
CN101716007A (zh) | 一种肉桂生姜保健饮料及其制备方法 | |
CN106418545A (zh) | 一种营养均衡的功能性食品 | |
CN105533688A (zh) | 一种辅助降血糖保健软胶囊及其制备方法 | |
CN107586672A (zh) | 一种刺梨保健酒及其制备方法 | |
CN101828714B (zh) | 一种用于延缓衰老的保健食品 | |
CN103609992A (zh) | 一种高丽红参膏的制备方法 | |
CN106511641A (zh) | 一种具有治疗痛风功效的青梅纳豆组合物及其制备方法 | |
CN102048225A (zh) | 一种具有改善生长发育功能的红枣保健饮料 | |
KR19990073127A (ko) | 건강보조발효식품의제조법 | |
CN1742971A (zh) | 砂仁山楂冲剂及其制备工艺 | |
CN108066712A (zh) | 一种补气养血中药组合物 | |
CN100574786C (zh) | 一种甲鱼制剂的生产工艺 | |
CN108813596A (zh) | 一种杜仲籽油软胶囊的制备方法及其应用 | |
CN110214902A (zh) | 一种儿童纠正偏食型富硒全营养粉 | |
CN1060028C (zh) | 一种主要由谷物瓜菜果组成的健康食品 | |
CN103549483A (zh) | 保健鳄鱼食品 | |
CN107594526A (zh) | 一种海藻胶为囊材的助消化软胶囊制剂的制备方法 | |
CN103798596B (zh) | 一种供心脑血管疾病患者食用的全营养配方食品 | |
CN112023010A (zh) | 一种瘦身用中药组合物及其制备方法、口服药剂和应用 | |
CN105495584A (zh) | 一种增强机体免疫力的以花生蛋白为主的食品生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181116 |